Intellia Therapeutics Inc.
NTLA | NASDAQ
$12.22
+$0.08 (+0.66%)
At close: Sep 21, 2026, 4:00 PM ET
$12.22
$0 (0.00%)
Pre-market:
Sep 22, 2026, 5:02 AM ET
Market Data
Market Cap $1.7B
Enterprise Value $1.34B
Beta 1.82
Average Volume 5.34M
Shares Outstanding (Diluted) 133.48M
Shares Change YoY 28.68%
Institutional Ownership 93.21%
Exchange NASDAQ
ISIN US45826J1051
Price Performance
Price Change 1M -3.0%
Price Change 3M -19.9%
Price Change 6M -7.8%
Price Change YTD 32.7%
Price Change 1Y -29.2%
Price Change 3Y -62.3%
Price Change 5Y -91.8%
1M CAGR (ann.) 8.0%
1Y CAGR (ann.) -2.2%
5Y CAGR (ann.) -40.3%
All-Time CAGR -5.6%
Valuation
PE Ratio -3.64
Forward PE 70.63
PEG Ratio -0.10
Forward PEG 0.21
PS Ratio 28.69
Forward PS 14.10
PB Ratio 2.35
P/FCF Ratio -3.66
P/Adj. FCF Ratio -2.75
P/OCF Ratio -3.51
EV/Sales 22.57
EV/EBIT -4.58
EV/EBITDA -4.70
EV/FCF -2.88
Earnings Yield -27.5%
FCF Yield -27.3%
Adj. FCF Yield -36.4%
Financial Health
Net Cash $364.35M
Total Debt $73.41M
Cash & Short-Term Investments $437.76M
Total Assets $857.16M
Current Ratio 6.65
Quick Ratio 6.65
Debt / Equity Ratio 0.10
Debt / EBITDA -0.26
Debt / FCF -0.16
OCF / Debt -6.32
Interest Coverage 0.00
Altman Z-Score 2.87
Piotroski F-Score 4
Margins & Profitability
Gross Profit Margin -46.5%
Operating Profit Margin -522.2%
EBITDA Margin -656.0%
Net Profit Margin -672.2%
FCF Margin -783.3%
Adj. FCF Margin -1044.5%
SBC / Revenue 261.2%
SBC Impact (per share) -33.4%
Returns
Return on Assets -46.7%
Return on Equity -57.8%
Return on Invested Capital -52.9%
Return on Capital Employed -54.5%
Return on Tangible Assets -46.7%
Historical Growth (CAGR)
Revenue CAGR 3Y 3.9%
Revenue CAGR 5Y 7.3%
Revenue CAGR 10Y 20.3%
EPS CAGR 3Y 23.5%
EPS CAGR 5Y 9.8%
EPS CAGR 10Y -11.4%
FCF CAGR 3Y -9.8%
FCF CAGR 5Y -7.1%
FCF CAGR 10Y -21.7%
Analyst Forecasts
Analyst Rating Buy
Analyst Count 39
EPS Growth Next 3Y 44.3%
Revenue Growth Next 3Y 153.1%
Earnings Date N/A
EPS Estimate (next Q) N/A
EPS Growth Est (next Q) N/A
Revenue Est (next Q) N/A
Revenue Growth Est (next Q) N/A
Fair Value Estimates
Graham Number N/A
Graham Upside N/A
Lynch Fair Value N/A
Lynch Upside N/A
Price Target $23
Price Target Upside 88.2%
Cash Flow
Operating Cash Flow $-463.99M
Free Cash Flow $-466.11M
Adj. Free Cash Flow $-621.54M
FCF Per Share -$3.49
OCF Per Share -$3.48
OCF/S Ratio -779.7%
Income Statement
Revenue $59.51M
Gross Profit $-35.32M
Operating Income $-310.72M
EBITDA $-285.83M
Net Income $-399.98M
EPS (Diluted) -$3.36
Revenue / Employee $157.84K
Profit / Employee $-1.06M
Employees 377
Add to Watchlist
Select watchlists to add or remove NTLA